** charts after earnings **
Kite Pharma beats by $0.02, beats on revs :
- Reports Q3 (Sep) loss of $0.38 per share, $0.02 better than the Capital IQ Consensus of ($0.40); revenues rose 50900.0% year/year to $5.1 mln vs the $4.67 mln Capital IQ Consensus.
- Kite's guidance remains unchanged. Kite expects to burn between $100 million and $125 million in cash for the full year 2015, which includes both operating expenses and capital expenditures. This guidance does not include cash inflows or outflows for business development activities.
- "Our ZUMA-1 trial is enrolling patients with aggressive, refractory non-Hodgkin's lymphoma, while our ZUMA-2 trial is enrolling patients with relapsed or refractory mantle cell lymphoma. We also plan to initiate two additional pivotal studies of KTE-C19 in patients with acute lymphoblastic leukemia prior to the end of this year. We look forward to reporting data from these trials in 2016 with the goal of filing our first Biologics License Application by the end of 2016."
No comments:
Post a Comment